Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output.

Liu J, Yang K, Yang J, Xiao W, Le Y, Yu F, Gu L, Lang S, Tian Q, Jin T, Wei R, Hong T

EBioMedicine1 Mar 2019Cited by 70 (Europe PMC)

PMID30827929PMCIDPMC6443026DOI10.1016/j.ebiom.2019.02.037PepBankPUB-30827929

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Mechanism
In hepatocytes, liraglutide stimulated the production of fibroblast growth factor 21 (FGF21).
In plain wordsIn lab-grown liver cells, liraglutide raised production of a liver hormone called FGF21.
Peptide
Liraglutide
Outcome
IncreaseFGF21 production in hepatocytes
Study
mouse, humann: not reported in source
Primary mouse and human hepatocytes, HepG2 cells
Outcome group
Receptor activity and mechanism · Liver
Studied dose
Dose not stated
Source sentences
Summary
Similarly, FGF21 production in hepatocytes was stimulated by exenatide or liraglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
The expression and secretion of fibroblast growth factor 21 (FGF21) in the livers of diabetic mice, primary mouse and human hepatocytes, and the human hepatic cell line HepG2 treated with or without GLP-1 analog were measured.
Report a problemFND-3082792901

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

02LabNot a test of Liraglutide aloneIn vitro (cells)Mechanism
In hepatocytes, blocking FGF21 weakened the inhibitory effect of the GLP-1 analogs exenatide and liraglutide on hepatic glucose output.
In plain wordsIn lab-grown liver cells, blocking FGF21 weakened the way GLP-1 drugs (exenatide and liraglutide) lower liver glucose output.
Peptide
Liraglutide
Outcome
DecreaseInhibition of hepatic glucose output after FGF21 blockage
Study
n: not reported in source
Hepatocytes with FGF21 neutralizing antibody or siRNA
Outcome group
Glycemic control · Liver
Source sentences
Summary
FGF21 blockage attenuated the inhibitory effects of the GLP-1 analogs on hepatic glucose output.
1 context sentence(design, population, supporting numbers)
Summary · context
The expression and secretion of fibroblast growth factor 21 (FGF21) in the livers of diabetic mice, primary mouse and human hepatocytes, and the human hepatic cell line HepG2 treated with or without GLP-1 analog were measured.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3082792902
03LabNot a test of Liraglutide aloneIn vitro (cells)Mechanism
In primary hepatocytes from Fgf21 knockout mice, the inhibitory effect of the GLP-1 analogs on hepatic glucose output was likewise weakened.
In plain wordsIn liver cells from mice lacking FGF21, GLP-1 drugs lowered liver glucose output less, as with FGF21 blockage.
Peptide
Liraglutide
Outcome
DecreaseInhibition of hepatic glucose output in Fgf21 knockout hepatocytes
Study
mousen: not reported in source
Primary hepatocytes from Fgf21 knockout mice
Outcome group
Glycemic control · Liver
Source sentences
Summary
FGF21 blockage attenuated the inhibitory effects of the GLP-1 analogs on hepatic glucose output. Similar results were also observed in primary hepatocytes from Fgf21 knockout mice.
1 context sentence(design, population, supporting numbers)
Summary · context
The expression and secretion of fibroblast growth factor 21 (FGF21) in the livers of diabetic mice, primary mouse and human hepatocytes, and the human hepatic cell line HepG2 treated with or without GLP-1 analog were measured.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3082792903

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.